GOSS · Gossamer Bio, Inc. · Analyst Estimates
$9.28
-0.17 (-1.80%)
At close · Nov 3
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company's existing cash and cash equivalents are not sufficient to fund operating plans for at least one year from the issuance date of these financial statements. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$57.75M
Shares
6.11M
Volume · Nov 3
139.45K
Avg daily vol (38 sessions)
273.69K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for Gossamer Bio, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-10-17 15:10 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-23.08
|
-18.01
|
-11.20
|
4
|
-16.32
|
-14.40
|
-31.91
|
-34.08
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
26.19M
|
40.51M
|
68.40M
|
7
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-28.80
|
-15.61
|
-2.88
|
5
|
-15.62
|
-14.48
|
-7.38
|
-7.73
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
16.73M
|
41.50M
|
7
|
— | — | — | — | — | — | — | — |
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-7.43
|
-3.93
|
0.80
|
5
|
-3.89
|
-3.77
|
-5.86
|
-6.55
|
0
|
0
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
0.00
|
12.16M
|
40.93M
|
7
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-6.40
|
-4.93
|
-3.20
|
5
|
-4.96
|
-4.40
|
-4.80
|
-5.14
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
3.01M
|
21.10M
|
7
|
— | — | — | — | — | — | — | — |
Key facts
CIK
1728117
CUSIP
38341P201
13F (30d)
20 filings
13 filers
Visit website
Investor relations